Sutro Biopharma (NASDAQ:STRO – Get Rating) had its target price boosted by Piper Sandler from $16.00 to $18.00 in a report published on Tuesday morning, The Fly reports. They currently have an overweight rating on the stock.

Separately, HC Wainwright reduced their target price on Sutro Biopharma from $30.00 to $20.00 and set a buy rating on the stock in a research report on Wednesday, November 9th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of Buy and a consensus target price of $19.00.

Sutro Biopharma Trading Up 4.9 %

Shares of NASDAQ:STRO opened at $7.67 on Tuesday. The business's 50-day moving average is $7.50 and its 200 day moving average is $6.48. Sutro Biopharma has a 1 year low of $3.33 and a 1 year high of $10.98. The firm has a market capitalization of $440.83 million, a P/E ratio of -2.96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.95 and a quick ratio of 5.95.

Institutional Trading of Sutro Biopharma

Large investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new stake in Sutro Biopharma during the 3rd quarter valued at about $37,000. Amalgamated Bank purchased a new stake in Sutro Biopharma during the 1st quarter valued at about $44,000. Point72 Hong Kong Ltd purchased a new stake in Sutro Biopharma during the 2nd quarter valued at about $46,000. Allspring Global Investments Holdings LLC purchased a new stake in Sutro Biopharma during the 3rd quarter valued at about $51,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Sutro Biopharma in the third quarter worth about $56,000. Hedge funds and other institutional investors own 87.64% of the company's stock.

Sutro Biopharma Company Profile

(Get Rating)

Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.

See Also

• Get a free copy of the StockNews.com research report on Sutro Biopharma (STRO)
• 3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
• Optimism About Global Demand For Metals Boosts BHP, Other Miners
• Exxon Mobil Expects Earnings and Cash Flow to Grow
• Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
• Is The Great Alibaba Recovery About To Begin?

Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.